Author Archives: Marta Figueiredo PhD

Top 10 SMA Stories of 2019

SMA News Today brought you daily coverage of key findings, treatment developments  — including in-depth coverage of Zolgensma’s approval in the U.S. — and of clinical trials related to spinal muscular atrophy (SMA) throughout 2019. We look forward to reporting more of this relevant news to patients, family members, and…

Spinraza Stabilizes or Improves Motor Function in Older SMA Patients, US Real-world Study Suggests

Spinraza (nusinersen) safely stabilizes or improves motor function in older patients with spinal muscular atrophy (SMA), according to a small U.S. real-world study. Researchers also pointed out that objective measures of meaningful improvements in daily life activities are required to better determine treatment effectiveness in this patient population.

Multidisciplinary Approach Improves Spinraza Dosing Process in SMA Patients, US Study Shows

Adopting a multidisciplinary approach can optimize pretreatment evaluations and improve the dosing process for Spinraza (nusinersen) in people with spinal muscular atrophy (SMA), a U.S. study shows. This approach, which also used computer simulations to optimize treatment schedules and reduce missed treatments, improved anesthetic methods and minimized complications associated with treatment…